上市公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | | 康龙化成（北京）生 | 子公司 | 其他应收款 | 12,193.28 | 12,000.00 | | 15,900.00 | 8,293.28 资金拆借 | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 物技术有限公司 | | | | | | | | | | | 康龙化成（成都）临 床研究服务有限公 | 子公司 | 其他应收款 | 3,007.30 | 9,700.00 | 76.36 | 3,023.82 | 9,759.84 资金拆借 | 非经营性往来 | | | 司 | | | | | | | | | | | 康瑞泰（湛江）生物 技术有限公司 | 子公司 | 其他应收款 | 2,600.00 | - | | 1,500.00 | 1,100.00 资金拆借 | 非经营性往来 | | | 康龙化成（西安）科 | 子公司 | 其他应收款 | 200.00 | 400.00 | | - | 600.00 资金拆借 ...

证券代码：300759 证券简称：康龙化成 公告编号：2023-075 康龙化成（北京）新药技术股份有限公司 关于公司实际控制人的一致行动人股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 截至公告披露日，上述实际控制人及其一致行动人所持股份质押情况如下： | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次解除 | 本次解除 | 占其 | 占公 | 情况 | | 情况 | | | | 持股数量 | 持股 | 质押前质 | 质押后质 | 所持 | 司总 | 已质押股 | 占已 | 未质押股 | 占未 | | 股东名称 | （股） | 比例 | 押股份数 | 押股份数 | 股份 | 股本 | | 质押 | | 质押 | | | | (%) | | | 比例 | 比例 | 份限售和 | 股份 | 份限售和 | 股份 | | | | | 量（股） | 量（股） | | | 冻 ...

证券代码：300759 证券简称：康龙化成 公告编号：2023-074 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）近日接到公 司实际控制人楼小强先生及其一致行动人宁波龙泰康投资管理有限公司（以下简 称"宁波龙泰康"）的函告，获悉楼小强先生和宁波龙泰康将其部分质押股份进 行补充质押及延期购回。具体事项如下： | 股东 | 是否为控 股股东或 第一大股 | 质押数量 | 占其 所持 | 占公司 总股本 | 是否 为限 | 是否 为补 | 质押起 | 质押到 | 延期购回 后质押到 | 质权人 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 东及其一 | （股） | 股份 | 比例 | 售股 | 充质 | 始日 | 期日 | 期日 | | 用途 | | | | | 比例 | | | 押 | | | | | | | | 致行动人 | | | | | | | | | | | | | | 注 1 | 1.65% | 0.04% | 否 | 是 | 2023 年 月 | 2023 年 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd.* 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2023年8月11日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事胡柏風先生及李家慶先生；獨立非執行董事周其林先生、李麗華女士、曾 坤鴻先生及余堅先生。 * 僅供識別 （股份代號：3759） 董事會會議通告 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於2023年8月25日（星期五）舉行，藉以（其中包括）審議及批准 本公司及其附屬公司截至2023年6月30日止六個月之中期業績。 ...

Incentive Plans - The company granted rewards under the 2022 A-share incentive plan on July 28, 2022, with the closing price prior to the grant being RMB 82.37[1] - The first phase of the H-share incentive trust plan granted rewards on April 1, 2022, and May 31, 2022, with closing prices of HKD 63.28 and HKD 59.38 respectively prior to the grants[1] Annual Report - The announcement does not affect other information disclosed in the 2022 annual report, which remains unchanged[2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd.* 康龍化成（北京）新藥技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 補充公告 有關截至2022年12月31日止年度的年報 的進一步資料 茲提述康龍化成（北京）新藥技術股份有限公司（「本公司」）截至2022年12月31日 止年度的年報（「2022年年報」）。除非另有定義，本公告所用詞彙與2022年年報所 界定者具有相同涵義。 除於2022年年報所載董事會報告「股份激勵計劃」一段及綜合財務報表附註40所披 露的資料外，本公司謹此提供有關根據上市規則第17.07(1)(c)條於報告期內根據 2022年A股激勵計劃及首期H股獎勵信託計劃授予各獎勵的進一步詳情。 於報告期內，本公司股份於緊接根據2022年A股激勵計劃及首期H股獎勵信託計 劃授予獎勵日期前的收市價載列如下： 2022年A股激勵計劃 ...

创业板投资风险提示 本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业融合存在 不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高等特点，投资者面 临较大的市场风险。投资者应充分了解创业板的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 安徽万邦医药科技股份有限公司 Anhui Wanbang Pharmaceutical Technology Co., Ltd. （安徽省合肥市高新区明珠大道与火龙地路交口西南角安徽万邦医药 1 号楼） 首次公开发行股票并在创业板上市 招股说明书 （注册稿） 公司的发行申请尚需经深圳证券交易所和中国证监会履行相应程序。本 招股说明书（注册稿）不具有据以发行股票的法律效力，仅供预先披露之 用。投资者应当以正式公告的招股说明书全文作为投资决定的依据。 保荐机构（主承销商） （中国（上海）自由贸易试验区浦明路 8 号） 安徽万邦医药科技股份有限公司 招股说明书（注册稿） 声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者 ...

Financial Performance - The company reported a revenue of CNY 2,723,970,949.97 for Q1 2023, representing a 29.53% increase compared to CNY 2,102,899,933.93 in the same period last year[4] - Net profit attributable to shareholders reached CNY 348,255,328.87, up 39.81% from CNY 249,086,573.60 year-on-year[4] - The adjusted net profit under non-IFRS was CNY 438,339,247.42, reflecting a 20.29% increase from CNY 364,396,375.05 in the previous year[4] - The company achieved a net cash flow from operating activities of CNY 530,139,954.34, which is a 26.89% increase from CNY 417,792,056.81 in the same quarter last year[4] - Total operating revenue for Q1 2023 reached CNY 2,723,970,949.97, a 29.5% increase from CNY 2,102,899,933.93 in Q1 2022[23] - Net profit for Q1 2023 was CNY 350,146,873.58, up 47.7% compared to CNY 236,952,176.60 in the same period last year[24] Earnings and Margins - The gross margin for the main business improved to 35.78%, up 2.61 percentage points from 33.17% in the previous year[8] - The basic earnings per share increased to CNY 0.2952, up 40.37% from CNY 0.2103 in the same period last year[4] - Basic earnings per share increased by 40.37% to 0.2952 compared to the same period last year, primarily due to an increase in net profit attributable to shareholders[12] - Diluted earnings per share rose by 40.59% to 0.2951, driven by the same factors as basic earnings[12] Cash Flow and Assets - Cash and cash equivalents increased by 372.6 million RMB, a growth of 37.26% from the beginning of the year[12] - The total current assets as of March 31, 2023, amounted to RMB 6,558,583,630.24, showing a slight increase from RMB 6,536,006,646.99 at the beginning of the year[20] - Cash and cash equivalents increased to RMB 2,055,504,003.16 from RMB 1,497,483,832.74, representing a growth of approximately 37%[20] - The company's long-term equity investments increased to RMB 638,223,819.28 from RMB 629,971,822.34, a rise of about 1.98%[20] - The total cash and cash equivalents at the end of Q1 2023 were CNY 1,990,475,525.11, a decrease from CNY 2,443,525,549.66 at the end of Q1 2022[27] Expenses and Investments - Research and development expenses surged by 93.81% to 76.84 million RMB, reflecting the company's commitment to enhancing R&D capabilities[12] - Management expenses rose by 42.63% to 414.38 million RMB, primarily due to an increase in personnel costs associated with business expansion[12] - Investment income increased significantly by 588.88% to 16.79 million RMB, attributed to higher investment returns from affiliated enterprises[12] - The company reported an investment income of CNY 16,791,039.74, a significant increase from CNY 2,437,442.71 in the previous year[23] Strategic Initiatives - The company continues to focus on a "full-process, integrated, and international" development strategy, with significant contributions from the top 20 global pharmaceutical companies[8] - The company announced a new equity incentive plan for 2023, aimed at aligning employee interests with company performance[18] - The company is actively participating in private equity investments, including a partnership with Wuxi AstraZeneca Zhongjin Venture Capital[17] - The company plans to expand its market presence through strategic investments and potential acquisitions in the biopharmaceutical sector[17] Liabilities and Equity - The total assets at the end of the reporting period were CNY 21,047,569,183.56, reflecting a 2.71% increase from CNY 20,492,557,228.07 at the end of the previous year[4] - Total liabilities rose to CNY 9,772,959,379.20, an increase from CNY 9,652,689,512.90, marking a 1.2% growth year-over-year[22] - The total equity attributable to shareholders of the parent company increased to CNY 10,979,426,501.16, up from CNY 10,548,615,357.20, reflecting a growth of 4.1%[22]

Financial Performance - The company reported a revenue of CNY 2,723,970,949.97 for Q1 2023, representing a 29.53% increase compared to CNY 2,102,899,933.93 in the same period last year[4] - Net profit attributable to shareholders reached CNY 348,255,328.87, up 39.81% from CNY 249,086,573.60 year-on-year[4] - The adjusted net profit attributable to shareholders under non-IFRS was CNY 438,339,247.42, reflecting a 20.29% increase from CNY 364,396,375.05 in the previous year[4] - Basic earnings per share increased by 40.37% to CNY 0.2952, driven by the overall positive development and expanding revenue scale[9] - The company reported a net profit of RMB 350,148,000 for the period, compared to RMB 236,953,000 in the previous year, marking an increase of about 47.7%[39] - For Q1 2023, the profit attributable to the parent company was RMB 348,255 thousand, an increase from RMB 249,087 thousand in Q1 2022[45] - The adjusted net profit attributable to the parent company under non-IFRS was RMB 438,339 thousand, reflecting a 20.3% increase compared to RMB 364,396 thousand in the same period last year[45] Revenue Breakdown - Revenue from laboratory services was CNY 1,652,771,147.35, with a year-on-year increase of 29.73%[5] - Revenue from North American clients accounted for 66.64% of total revenue, growing 34.74% year-on-year[6] - Revenue from European clients (including the UK) represented 14.81% of total revenue, increasing by 38.12% compared to the previous year[6] Cost and Expenses - Total operating costs amounted to ¥2,352,273,096.85, up 28% from ¥1,838,358,908.07 in the prior period[21] - Research and development expenses surged by 93.81% to CNY 76,838,901.31, reflecting the company's commitment to enhancing R&D capabilities[10] - Research and development expenses increased to ¥76,838,901.31, up 93.9% from ¥39,647,299.50 in the prior period, highlighting a focus on innovation[23] Cash Flow and Liquidity - Cash flow from operating activities for the period was CNY 530,139,954.34, a 26.89% increase from CNY 417,792,056.81 in the previous year[4] - Cash and cash equivalents rose by 37.26% to CNY 2,055,504,003.16, an increase of CNY 558,020,200[9] - Cash and cash equivalents at the end of the period amounted to RMB 1,990,475,525.11, compared to RMB 2,443,525,549.66 at the end of the previous period[35] Assets and Liabilities - The total current assets as of March 31, 2023, amounted to CNY 6,558,583,630.24, showing a slight increase from CNY 6,536,006,646.99 at the beginning of the year[16] - The total non-current assets reached CNY 14,488,985,553.32, compared to CNY 13,956,550,581.08 at the beginning of the year, reflecting a growth of approximately 3.8%[17] - Total liabilities increased to ¥9,772,959,379.20 from ¥9,652,689,512.90 at the beginning of the year, marking a rise of 1.2%[19] - Non-current liabilities totaled RMB 5,838,198 thousand as of March 31, 2023, compared to RMB 5,740,256 thousand at the end of 2022[42] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 63,326[11] - The largest shareholder, HKSCC NOMINEES LIMITED, held 16.87% of the shares, totaling 201,001,393 shares[12] - The company's major shareholders include HKSCC NOMINEES LIMITED with 201,001,393 shares and Shenzhen Xinchongkangcheng Investment Partnership with 178,735,472 shares[13] Strategic Focus - The company continues to focus on a "full-process, integrated, and international" development strategy, with significant business presence in both China and overseas markets[6] - The company has completed the integration of its capabilities in large molecule and cell and gene therapy services, enhancing its service offerings[5] Other Financial Metrics - The company received government subsidies related to daily activities amounting to CNY 18,969,599.72, which contributed to other income growth of 108.49%[10] - The company reported a total comprehensive income of ¥349,276,609.52 for the current period, significantly higher than ¥181,924,551.84 in the previous period[28] - The total liabilities to equity ratio stands at approximately 86.7%, indicating a stable leverage position for the company[19]

希格玛会计师事务所(特殊普通合伙) Xigema Cpas(Special General Partnership) 关于新疆百花村医药集团股份有限公司 非公开发行股票项目反馈意见的回复 中国证券监督管理委员会: 根据贵会 2022年3月7日下发的《中国证监会行政许可项目审查一次反馈意 见通知书》(220241 号)(以下简称"《反馈意见》")的要求,我们在审慎调查的基 础上,就《反馈意见》的相关问题作出如下答复: 反馈意见 9: 申请人于 2016 年完成资产置出并置入华威医药 CRO 业务资产, CRO 业务收入为申请人报告期内最主要的收入来源。最近三年一期,申请人扣非归 母净利润分别-68,622.79 万元、731.11 万元、 -36,923.75 万元、595.78 万元, 其中 2020 年营业收入 8,453.04 万元。公司股票于 2021 年 4 月 1 日起被实施 "退市风险警示"。请申请人:(1)说明报告期内业绩大幅波动的主要原因,业绩 大亏与微利交替出现的原因及合理性,是否与同行业公司一致,是否存在操纵公 司业绩规避退市等情况;(2)结合上述情况说明申请人持续经营是否存在重大风 险, ...